MiNA Therapeutics

MiNA Therapeutics: Versatile, proprietary small activating ribonucleic acid (saRNA) therapeutics platform, analogous to RNAi opportunity, and internal pipeline initially focusing on oncology and rare disease indications. Clinical proof of concept achieved in 2020 for first saRNA, with next study aimed at potential accelerated approval in 2024. Advancing 10 different saRNA assets (some in multiple indications) into the clinic by 2025. Initiating randomized Ph2 study for lead RNAa drug candidate MTL-CEBPA combined with sorafenib in second line hepatocellular carcinoma in 1Q22. Ph1b readout in solid tumors (MTL-CEBPA+Pembro PD-1) in 1Q22. Raised $30M Series A lead by aMoon (Sep 2020). $1.5B+ partnerships with Eli Lilly, Servier, AstraZeneca; $25M upfront from recent Lilly deal.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Investment Participation
Series A
Listing
Private
Market Cap
Private
Therapeutic Modalities
Platform Technology
Website:
Profiles:
Address:
84 Wood Lane
London, England W12 0BZ
United Kingdom

Company Participants at Spring Private Company Showcase

Robert Habib
MiNa Therapeutics, Chief Executive Officer
Robert joined MiNA as founding Chief Executive Officer in 2013. Robert has overseen MiNA’s growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners. During his tenure MiNA has established itself as the leader in saRNA therapeutics, attracting over $100m of funding. Prior to joining MiNA, Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.
Robin Wright
MiNa Therapeutics, CFO
Robin was appointed Chief Financial Officer in 2021. He has over three decades of experience in over 250 financing transactions and 170 M&A transactions, with previous CFO roles at listed biopharmaceutical companies Pharming Group NV, Karolinska Development AB and Orexo AB. Prior to this, Robin held senior roles in private equity and investment banking, including Head of European Pharma & Chemicals M&A at Citibank Salomon Smith Barney. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Robin is also non-executive chairman of Vaccitech.